Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca chases Acerta to secure next cancer drug winner

AstraZeneca said on Monday it was in talks that might lead to the acquisition of privately held biotech firm Acerta Pharma, a potential $5 billion-plus deal designed to build up its cancer drug portfolio.   “AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any […]

Read More »

Reckitt Benckiser misled consumers on Nurofen painkillers: Australian court

An Australian court ordered Reckitt Benckiser to pull several of its Nurofen pain relief products from the market, saying on Monday the British firm had misled consumers by marketing identical products for different types of pain.   The Federal Court ruled that the Nurofen Back Pain, Period Pain, Migraine Pain and Tension Headache products were […]

Read More »

Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition

Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call Today at 8 a.m. ET to Discuss Transaction DUBLIN, IRELAND–(Marketwired – Dec 11, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on […]

Read More »

UK cost agency endorses Novartis heart drug for some patients

Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment was a cost-effective option.   Entresto has a list price of 1,194 pounds ($1,809) a year in Britain, or less than half the price of […]

Read More »

Sales and Marketing: IMS projects narrowing use gap, slowing med spend growth over next five years

More than half of the world’s population will live in countries where medicine use will exceed one dose per person per day by 2020, up from 31 percent in 2005, as the “medicine use gap” between developed and pharmerging markets narrows, according to research by the IMS Institute for Healthcare Informatics.

Read More »

Senate panel focuses on toll of Valeant, Turing drug price spikes

A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection.   In Utah, a hospital has been forced to change the way it stocks a drug critical to treating heart patients after the cost skyrocketed from […]

Read More »

Trial for Bayer’s Xarelto under scrutiny over defective device

European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer’s top-selling anti-clotting drug Xarelto, hitting the German drugmaker’s shares. The study compared Xarelto, also known as rivaroxaban, with older drug warfarin for preventing strokes in patients with a type of irregular heartbeat common among the […]

Read More »

Teva gets FDA approval for cancer drug

Israel’s Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, […]

Read More »

Tonix Pharma, U.S. Defense Department partner on PTSD drug

Tonix Pharmaceuticals Holding Corp said it was teaming up with the U.S. Department of Defense to further develop its experimental PTSD drug, which if approved, could be the first treatment for the psychiatric disorder in more than 15 years. The Cooperative Research and Development Agreement with the Department of Defense will allow Tonix to gain […]

Read More »

Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom